According to a recent LinkedIn post from Zeto Inc, the company is highlighting a new product called Zeto New Wave™, aimed at outpatient electroencephalograms (EEGs). The post suggests the system is designed to address long patient wait times in the U.S. and operational challenges such as staffing shortages and complex clinical workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post describes New Wave™ as offering full head coverage with 21 soft-tip, no-mess electrodes using the standard 10–20 system, along with an all-in-one recording device. It also notes features such as synchronized video, audio, and optional signals, positioning the product as a comprehensive neurodiagnostic solution for clinics.
The post cites CEO Florian Strelzyk, PhD, as emphasizing that neurologist feedback influenced the design, with a focus on expanding access to EEG, easing staffing pressures, and improving patient experience. For investors, this focus on workflow efficiency and access could indicate a strategy to deepen penetration in outpatient neurology settings, where scalable, easy-to-use systems can be a key differentiator.
If successfully adopted, the product could support recurring revenue opportunities through increased procedure volumes and potentially higher utilization of Zeto’s broader ecosystem. In the competitive MedTech and neurodiagnostics market, such a solution may enhance Zeto Inc’s positioning against traditional EEG systems and newer digital entrants, though actual financial impact will depend on reimbursement, purchasing cycles, and clinical adoption rates.